Biotechnology News and Research

RSS

Activation mechanism of protective protein in ocular lens resolved

The lens of the human eye is made up of a highly concentrated protein solution that imparts the eye its high refractive power. Yet, despite this high protein content the ocular lens must remain clear and transparent.

24 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

...

23 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

...

23 Oct 2013

Startup Wins Five-Year Exclusive License To Decode Genetics Platform

...

23 Oct 2013

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

23 Oct 2013

Amgen Buys Roche Rights To Neutropenia Drugs

...

22 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

PDL Biopharma Acquires Diabetes Royalty, Milestone Rights For $240.5M

...

22 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

CUMC develops new technique that uses patient's own cells to grow new hair

Researchers at Columbia University Medical Center (CUMC) have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one part of the scalp to another.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

U.K. Organizations Partner With Illumina To Sequence 10,000 Whole Genomes

...

From Illumina, Inc. 21 Oct 2013

Medmira Wins Additional $1.9M Army Contract

...

21 Oct 2013

Astrazeneca, Evotec Launch Kidney Disease Collaboration

...

21 Oct 2013

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.

21 Oct 2013

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

21 Oct 2013

Advaxis announces full exercise of over-allotment option granted to underwriters

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.

19 Oct 2013